About Retatrutide-RX.com — Written by a Practicing PA-C

Who Writes This Site

Site Author & Editor

Jim Giannakakis, PA-C

Emergency Medicine PA-C Emory University Hospital · Decatur, GA NCCPA Certified

I'm a practicing Physician Assistant-Certified working in Emergency Medicine at Emory University Hospital in Decatur, Georgia. I've been following the GLP-1 drug class closely since semaglutide's early trials — both as a clinician managing patients with obesity and type 2 diabetes, and as someone who finds the underlying pharmacology genuinely fascinating.

Retatrutide caught my attention when the Phase 2 NEJM paper landed in 2023. The 24.2% weight loss number was unlike anything the field had seen from a non-surgical intervention, and the triple agonist mechanism raised questions that I wanted to track carefully as the Phase 3 program unfolded.

I built this site because I wanted a resource that treated readers as intelligent adults — with accurate clinical data, honest uncertainty where it exists, and none of the hype that dominates most GLP-1 content online. As a PA-C I read the primary literature regularly. Everything on this site is grounded in published trial data, Eli Lilly press releases, and peer-reviewed sources.

What This Site Is

Retatrutide-RX.com is an independent educational and reference resource covering retatrutide (LY3437943) — Eli Lilly's investigational triple receptor agonist currently in Phase 3 clinical trials. The site covers:

Clinical trial data — detailed breakdowns of TRIUMPH Phase 2 and Phase 3 results as they are published, including the most recent TRANSCEND-T2D-1 diabetes data from April 2026.

Drug comparisons — honest, data-driven comparisons of retatrutide against approved GLP-1 drugs (semaglutide, tirzepatide) and pipeline competitors (CagriSema, orforglipron).

Research access information — for people researching the research peptide market, we maintain a verified vendor comparison page with third-party testing information and current pricing.

FDA regulatory coverage — the approval timeline, what the regulatory pathway looks like, and what commercial availability will mean for pricing and access.

What This Site Is Not

This site is not affiliated with Eli Lilly and Company. It is not a medical practice and does not provide medical advice. Nothing here should be used to make treatment decisions — that requires a conversation with a licensed healthcare provider who knows your individual health history.

Retatrutide is an investigational drug not approved by the FDA. Research peptides sold as "for laboratory use only" are not FDA-regulated medications. The site covers both the clinical trial landscape and the research peptide market as informational resources — not as recommendations for any particular course of action.

Affiliate Disclosure

This site contains affiliate links to research peptide vendors. If you purchase through these links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial coverage — we write about what the trial data shows regardless of which vendors we work with. We only list vendors we have independently researched and would be comfortable recommending to our own readers.

Our standard for vendor recommendations: Third-party COA from a named, verifiable external laboratory. HPLC and mass spectrometry documentation. Positive community track record on r/Peptides. Verifiable US business information. We remove vendors who don't maintain these standards.

Sources & Editorial Standards

Primary sources used on this site include: Eli Lilly investor relations press releases, peer-reviewed publications in the New England Journal of Medicine, The Lancet, and other indexed journals, ClinicalTrials.gov trial registrations, FDA regulatory filings, and reporting from Pharmacy Times, BioSpace, and other medically-focused outlets.

All trial data figures are cited to their source. Where projections or analyst estimates are presented, they are clearly labeled as such rather than presented as established facts. The site is updated regularly as new TRIUMPH data is published — check the news page for the latest.

Medical Disclaimer: The information on Retatrutide-RX.com is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved by the FDA. Do not make healthcare decisions based on this content. Always consult a licensed healthcare professional. Not affiliated with Eli Lilly and Company.